Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function

Li, Xiang; Luo, Lihua; Jiang, Mengshi; Zhu, Chunqi; Shi, Yingying; Zhang, Junlei; Qin, Bing; Luo, Zhenyu; Guo, Xuemeng; Lu, Yichao; Shan, Xinyu; Liu, Yu; Du, Yong‐Zhong; Peng, Ling; You, Jian

doi:10.1016/j.jconrel.2021.05.002

Cited by 24 publications

(11 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Galectin-3 has been involved as a major determinant of cold tumors (those which do not respond to immune checkpoint inhibitors due to the paucity of tumor T cell infiltration, as happens in prostate and pancreas adenocarcinomas); galectin-3 inhibition can reverse such resistance [363]. Consequently, inhibition of galectin-3 in tumor cells leads to an optimal anti-prostate cancer vaccination [199].…”

Section: Discussionmentioning

confidence: 99%

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure

Laderach

Compagno

2021

Cancers

View full text Add to dashboard Cite

Current data indicates that anti-tumor T cell-mediated immunity correlates with a better prognosis in cancer patients. However, it has widely been demonstrated that tumor cells negatively manage immune attack by activating several immune-suppressive mechanisms. It is, therefore, essential to fully understand how lymphocytes are activated in a tumor microenvironment and, above all, how to prevent these cells from becoming dysfunctional. Tumors produce galectins-1, -3, -7, -8, and -9 as one of the major molecular mechanisms to evade immune control of tumor development. These galectins impact different steps in the establishment of the anti-tumor immune responses. Here, we carry out a critical dissection on the mechanisms through which tumor-derived galectins can influence the production and the functionality of anti-tumor T lymphocytes. This knowledge may help us design more effective immunotherapies to treat human cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure

Laderach

Compagno

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Similarly, TNBC features immunological “cold” tumor, which with limited tumor infiltrating lymphocytes ( 72 ). To address this problem, we need to find a methodological strategy that actively recruits CD8 + T cells into the tumor microenvironment (TME), reverses “cold” tumors into “hot” tumors, and significantly improves their reactivity to ICIs ( 73 ).…”

Section: Combination Therapymentioning

confidence: 99%

Prospects of Immunotherapy for Triple-Negative Breast Cancer

et al. 2022

View full text Add to dashboard Cite

In the classification and typing of breast cancer, triple-negative breast cancer (TNBC) is one type of refractory breast cancer, while chemotherapy stays in the traditional treatment methods. However, the impact of chemotherapy is short-lived and may lead to recurrence due to incomplete killing of tumor cells. The occurrence, development, and relapse of breast cancer are relevant to T cell dysfunction, multiplied expression of related immune checkpoint molecules (ICIs) such as programmed death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) produce immunosuppressive effect. Immunotherapy (namely, immune checkpoint inhibitors, adoptive cellular immunotherapy, CAR-T immunotherapy and some potential treatments) provides new hope in TNBC. This review focuses on the new immune strategies of TNBC patients.

show abstract

“…G3-C12@PLGA not only maintained CXCL9/10 concentrations in tumor tissues for a long time by releasing IFN-γ and continuously recruiting CD8 + T cells into tumors, but also helped anti-PD-1 peptide to function better. The combination of the two significantly inhibited the increase of ascites, reduced the metastasis of peritoneal tumors, prolonged the survival of model mice, and offered the possibility of a cure for OC ( 151 ).…”

Section: Application Of Ifn Responsementioning

confidence: 99%

The role of interferons in ovarian cancer progression: Hinderer or promoter?

Liu

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Ovarian cancer (OC) is a common gynecologic malignancy with poor prognosis and high mortality. Changes in the OC microenvironment are closely related to the genesis, invasion, metastasis, recurrence, and drug-resistance. The OC microenvironment is regulated by Interferons (IFNs) known as a type of important cytokines. IFNs have a bidirectional regulation for OC cells growth and survival. Meanwhile, IFNs positively regulate the recruitment, differentiation and activation of immune cells. This review summarizes the secretion and the role of IFNs. In particular, we mainly elucidate the actions played by IFNs in various types of therapy. IFNs assist radiotherapy, targeted therapy, immunotherapy and biotherapy for OC, except for some IFN pathways that may cause chemo-resistance. In addition, we present some advances in OC treatment with the help of IFN pathways. IFNs have the ability to powerfully modulate the tumor microenvironment and can potentially provide new combination strategies for OC treatment.

show abstract

Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function

Cited by 24 publications

References 58 publications

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure

Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure

Prospects of Immunotherapy for Triple-Negative Breast Cancer

The role of interferons in ovarian cancer progression: Hinderer or promoter?

Contact Info

Product

Resources

About